Abstract:Background and Objective We have reported previously that genetic or pharmacological inhibition of angiotensinogen (AGT) leads to resistance to dietary fat-induced body weight gain. This phenotype has not been observed in mice subject to pharmacological inhibitors of other components of the renin angiotensin system including renin, ACE, and AT1 receptors. To investigate whether restoration of AGT reverses this lean phenotype, we injected an adeno-associated virus (AAV) 2/8 vector carrying wild type AGT to mice with hepatocyte-specific deficiency of AGT (hepAGT -/-). Methods and Results HepAGT -/- mice were generated by disrupting AGT gene in hepatocytes via albumin promoter driven Cre recombinase expressed in mice with floxed AGT alleles. An AAV AGT vector was constructed with the insertion of wild type AGT. AAV null vector was used as control. AAV expression was driven by hepatocyte-specific thyroxine-binding globulin promoter. Five groups of male LDL receptor -/- mice at age of 8 - 10 weeks were studied: wild type (hepAGT +/+) mice received either no AAV (PBS) or null AAV, and hepAGT -/- mice received low dose (1 x 1010 genome copy), high dose (3 x 1010 genome copy), or null AAV. Four weeks after AAV injection (i.p.), all mice were fed a saturated fat-enriched diet (42% calories from milk fat) for 12 weeks. Plasma samples were collected through retro-orbital bleeding at weeks 2, 4, 8, and 16 after AAV injection. Plasma AGT concentrations peaked between weeks 2 and 4, then declined modestly, irrespective of dosage. However, at the high dose, plasma AGT concentrations in hepAGT -/- mice were comparable to those in hepAGT +/+ mice. Plasma total cholesterol concentrations, body weight gains, and systolic blood pressures were not different between hepAGT +/+ and hepAGT -/- mice receiving either dose of AGT AAV. Atherosclerosis, quantified as percent lesion area covering the intima of the aortic arch, was equivalent between hepAGT -/- mice receiving either dose of AGT AAV and hepAGT +/+ mice, whereas it was nearly absent in hepAGT -/- mice receiving null AAV. Conclusions AGT in an AAV 2/8 vector efficiently recovers plasma AGT concentration in hepAGT -/- mice in a dose-dependent manner. This approach permits the elucidation of structural mutations on AGT function.

Abstract 352: Adeno-Associated Virus-mediated Restoration of Angiotensinogen Function in Mice with Hepatocyte-specific Deficiency

In Vivo Targeted Delivery of ANGPTL8 Gene for Beta Cell Regeneration in Rats

Cys18-Cys137 Disulfide Bond in Mouse Angiotensinogen Does Not Affect AngII-dependent Functions in Vivo.

ANGPTL8 Reverses Established Adriamycin Cardiomyopathy by Stimulating Adult Cardiac Progenitor Cells.

Abstract 5457: Angiotensinogen Hypomorphic Mice Have Markedly Reduced Hypercholesterolemia-induced Atherosclerosis

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Angiotensinogen Inhibition Reduces Atherosclerosis And Body Weight Gain Induced By High-Carbohydrate Diet

Angiotensinogen in Hepatocytes Contributes to Western Diet-Induced Liver Steatosis

Effects of Human Angiotensinogen and Human Renin in Proximal Tubule Cells on Development of Atherosclerosis in Hypercholesterolemic Mice

Hepatocyte-Specific Angiotensinogen Deficiency Markedly Reduces Hypercholesterolemia-Induced Atherosclerosis And Diet-Induced Obesity In Mice

Abstract 636: Angiotensinogen and Megalin Interaction Contribute to Renal Angiotensin II Production and Hypercholesterolemia-induced Atherosclerosis

Abstract 227: Megalin Regulates Angiotensinogen and Contributes to Atherosclerosis

Hepatorenal Correction in Murine Glycogen Storage Disease Type I with A Double-Stranded Adeno-Associated Virus Vector

Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPLS447XBeneficial Mutation

Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver

40. Correction of Dyslipidemia in Murine and Feline Models of Lipoprotein Lipase Deficiency by Intramuscular Administration of AAV1-LPLS447X

Preclinical evaluation of tissue-selective gene therapies for congenital generalised lipodystrophy

In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency

Novel Transgenic Humanized Alpha-1 Antitrypsin Deficiency Mouse Model on Murine SERPINA1 Null Background

Hepatocyte-Specific Fads1 Overexpression Attenuates Western Diet-Induced Metabolic Phenotypes in a Rat Model

Inhibition of Atherogenesis in LDLR Knockout Mice by Systemic Delivery of Adeno-Associated Virus Type 2-Hil-10.